Third generation antipsychotic drugs: Partial agonism or receptor functional selectivity?

Current Pharmaceutical Design

Volumn 16, Issue 5, 2010, Pages 488-501

  Mailman, Richard B ^a   Murthy, Vishakantha ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Antipsychotic drugs; Dopamine receptors; Drug action; Functional selectivity; G protein coupled receptors; Receptor mechanisms; Schizophrenia; Serotonin receptors

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ARACHIDONIC ACID; ARIPIPRAZOLE; BETA ARRESTIN; CHLOROPROCAINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; LEVODOPA; LIPOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE; N N PROPYLDIHYDREXIDINE; NEUROLEPTIC AGENT; OLANZAPINE; PHOSPHOLIPASE A2; PROLACTIN; PROSTAGLANDIN SYNTHASE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; THIORIDAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE;

DOPAMINE RELEASE; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PARKINSON DISEASE; PARTIAL AGONISM; PRIORITY JOURNAL; PROLACTIN RELEASE; PSYCHOSIS; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; WEIGHT GAIN;

EID: 77949458560     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790361461     Document Type: Review

References (170)

1. Delay J, Deniker P, Harl JM. Therapeutic method derived from hiberno-therapy in excitation and agitation states. Ann Med Psychol (Paris) 1952; 110: 267-73.
2. Carlsson A, Lindqvist M. Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 1963; 20: 140-4.
3. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-3.
4. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol Scand Suppl 1971; 367: 1-48.
5. Kebabian JW, Petzold GL, Greengard P. Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor". Proc Natl Acad Sci USA 1972; 69: 2145-9.
6. Clement-Cormier YC, Kebabian JW, Petzold GL, Greengard P. Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs. Proc Natl Acad Sci USA 1974; 71: 1113-7.
7. Iversen LL. Dopamine receptors in the brain. Science 1975; 188: 1084-9.
8. Trabucchi M, Longoni R, Fresia P, Spano PF. Sulpiride: a study of the effects on dopamine receptors in rat neostriatum and limbic forebrain. Life Sci 1975; 17: 1551-6.
9. Garau L, Govoni S, Stefanini E, Trabucchi M, Spano PF. Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum. Life Sci 1978; 23: 1745-50.
10. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979; 277: 93-6.
11. Neve KA, Neve RL. The dopamine receptors. Totowa, N.J. Humana Press 1997.
12. Jenner P and Demirdemar R. Dopamine receptor sub-types: from basic sciences to clinical applications. Burke, VA, 1997 IOS Press,
13. Sealfon SC, Olanow CW. Dopamine receptors: from structure to behavior. Trends Neurosci 2000; 23: S34-40.
14. 1 dopamine receptors. Int Rev Neurobiol 2001; 48: 65-139.
15. 1 dopamine receptor. Nature 1990; 347: 72-6.
16. 1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci USA 1990; 87: 6723-7.
17. 1 dopamine receptors. Nature 1990; 347: 76-80.
18. 5 receptor with higher affinity for dopamine than D1. Nature 1991; 350: 614-9.
19. 2 receptor: two molecular forms generated by alternative splicing. EMBO J 1989; 8: 4025-34.
20. 2 dopamine receptor isoforms. Nature 1989; 342: 923-6.
21. 2 dopamine receptors produced by alternative RNA splicing. Nature 1989; 342: 926-9.
22. 2 dopamine receptor in rat and bovine caudate nucleus. Nature 1990; 343: 266-9.
23. 3) as a target for neuroleptics. Nature 1990; 347: 146-51.
24. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-4.
25. 4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biol 1992; 4: 137-46.
26. 4 receptor gene: evidence of association but no linkage in a UK sample. Mol Psychiatry 2001; 6: 440-4.
27. Schmidt LA, Fox NA, Perez-Edgar K, Hu S, Hamer DH. Association of DRD4 with attention problems in normal childhood development. Psychiatr Genet 2001; 11: 25-9.
28. 4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): a family-based approach. Mol Psychiatry 1998; 3: 38-41.
29. 4 receptor gene variants and novelty seeking. Mol Psychiatry 2002; 7: 18-20.
30. Jonsson EG, Ivo R, Forslund K, Mattila-Evenden M, Rylander G, Cichon S, et al. No association between a promoter dopamine D(4) receptor gene variant and schizophrenia. Am J Med Genet 2001; 105: 525-8.
31. 4 exon III repeat polymorphism in ADHD in a family-based study. Am J Med Genet 2000; 96: 278-81.
32. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989; 50: 322-8.
33. Fleischhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural Transm Suppl 2003;105-17.
34. Barnes TR, McPhillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry Suppl 1999; 34-43.
35. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999; 46: 1396-408.
36. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10: 79-104.
37. Miyamoto S, Duncan GE, Mailman RB, Lieberman JA. Developing novel antipsychotic drugs: strategies and goals. Curr Opin CPNS Invest Drugs 2000; 2: 25-39.
38. Kane J. Olanzapine in the long-term treatment of schizophrenia. Br J Psychiatry Suppl 1999; 26-9.
39. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996; 57 (Suppl 11): 68-71.
40. Meyer JM, Simpson GM. From chlorpromazine to olanzapine: a brief history of antipsychotics. Psychiatr Serv 1997; 48: 1137-9.
41. Niedzwiecki DM, Mailman RB, Cubeddu LX. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors. J Pharmacol Exp Ther 1984; 228: 636-9.
42. Niedzwiecki DM, Cubeddu LX, Mailman RB. Comparative anticholinergic properties of thioridazine, mesoridazine and sulforidazine. J Pharmacol Exp Ther 1989; 250: 126-33.
43. Niedzwiecki DM, Cubeddu LX, Mailman RB. Comparative antidopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum. J Pharmacol Exp Ther 1989; 250: 117-25.
44. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96.
45. Lieberman J, Johns C, Cooper T, Pollack S, Kane J. Clozapine pharmacology and tardive dyskinesia. Psychopharmacology 1989; (99 Suppl): S54-9.
46. Lieberman JA. Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. Br J Psychiatry Suppl 1993; 7-18.
47. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96.
48. Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs. Ann Pharmacother 1999; 33: 210-7.
49. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004; 3: 353-9.
50. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009; 107: 1-12.
51. Huttunen M. The evolution of the Serotonin-Dopamine Antagonist Concept. J Clin Psychopharmacol 1995; 15: 4S-10.
52. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989; 25: 390-2.
53. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999; 33: 73-85.
54. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995; 15: 36S-44.
55. Feenstra MG, Sumners C, Goedemoed JH, de Vries JB, Rollema H, Horn AS. A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity. Naunyn Schmiedebergs Arch Pharmacol 1983; 324: 108-15.
56. Meller E, Bohmaker K, Namba Y, Friedhoff AJ, Goldstein M. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol Pharmacol 1987; 31: 592-8.
57. Kenakin TP. Pharmacologic analysis of drug-receptor interaction. Philadelphia 1997, Lippincott-Raven Publishers,.
58. Tamminga CA, Schaffer MH, Smith RC, Davis JM. Schizophrenic symptoms improve with apomorphine. Science 1978; 200: 567-8.
59. Corsini GU, Pitzalis GF, Bernardi F, Bocchetta A, Del ZM. The use of dopamine agonists in the treatment of schizophrenia. Neuropharmacology 1981; 20: 1309-13.
60. Smith RC, Tamminga C, Davis JM. Effect of apomorphine on schizophrenic symptoms. J Neural Transm 1977; 40: 171-6.
61. Tamminga CA, Gotts MD, Thaker GK, Alphs LD, Foster NL. Dopamine agonist treatment of schizophrenia with Npropylnorapomorphine. Arch Gen Psychiatry 1986; 43: 398-402.
62. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl) -N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry 1998; 43: 2-11.
63. Tamminga CA, Cascella NG, Lahti RA, Lindberg M, Carlsson A. Pharmacologic properties of (-)-3PPP (preclamol) in man. J Neural Transm Gen Sect 1992; 88: 165-75.
64. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 2002; 109: 411-20.
65. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001; 62: 841-2.
66. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004; 18: 251-67.
67. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20: 612-27.
68. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-9.
69. Shapiro DA, Renock S, Arrington E, Sibley DR, Chiodo LA, Roth BL, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400-11.
70. Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has Functionally Selective Actions at Dopamine D(2) Receptor-Mediated Signaling Pathways. Neuropsychopharmacology 2007; 32: 67-77.
71. 2 receptor antagonistic activity. J Pharmacol Exp Ther 1995; 274: 329-36.
72. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007; 320: 1-13.
73. Stephenson RP. A modification of receptor theory. Br J Pharmacol 1956; 11: 379-93.
74. Kenakin T. Pharmacologic analysis of drug-receptor interaction. Philadelphia, Lippincott-Raven 1997.
75. Furchgott RF. The use of -haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In: Harper NJ, Simmonds AB, Eds. Advances in drug research. New York: Academic Press 1966; pp. 21-55,.
76. Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, et al. Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. Eur J Pharmacol 1989; 166: 111-3.
77. 1 full agonist. J Med Chem 1990; 33: 1756-64.
78. 1 dopamine receptor agonist. J Pharmacol Exp Ther 1992; 262: 383-93.
79. 2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 2002; 301: 1166-78.
80. Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS, et al. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 2002; 301: 1179-89.
81. Mailman RB, Nichols DE, Lewis MM, Blake BL, Lawler CP. Functional effects of novel dopamine ligands: dihydrexidine and Parkinson's disease as a first step. In: Jenner P, Demirdemar R, Eds. Dopamine receptor subtypes: from basic science to clinical application. IOS: Stockton Press 1998; pp. 64-83.
82. Roth BL, Chuang DM. Multiple mechanisms of serotonergic signal transduction. Life Sci 1987; 41: 1051-64.
83. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 1998; 54: 94-104.
84. 1 dopamine receptor agonist. Neuropsychopharmacology 1991; 5: 187-95.
85. Eden RJ, Costall B, Domeney AM, Gerrard PA, Harvey CA, Kelly ME, et al. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav 1991; 38: 147-54.
86. 2 post-synaptic receptor agonist. Eur J Pharmacol 1997; 323: 27-36.
87. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy- dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970; 24: 485-93.
88. Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006; 21: 2078-81.
89. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 2004; 24: 165-205.
90. Mailman RB, Wang Y-M, Kant A, and Brown JT. Functional selectivity of dopamine receptors. In: Neve KA, Ed. Functional selectivity of G protein-coupled receptor ligands. Humana, New York: 2009; pp. 177-209.
91. De Camilli P, Macconi D, Spada A. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 1979; 278: 252-4.
92. Stoof JC, Kebabian JW. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 1981; 294: 366-8.
93. Huff RM. Signaling pathways modulated by dopamine receptors. in: Neve KA, Neve RL, Eds. The dopamine receptors. Totowa, NJ. Humana Press 1997; pp. 167-192.
94. 2-like dopamine receptors. Adv Pharmacol 1998; 42: 454-7.
95. Oxford GS, Wagoner PK. The inactivating K+ current in GH3 pituitary cells and its modification by chemical reagents. J Physiol (Lond) 1989; 410: 587-612.
96. 2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. J Physiol (Lond) 1987; 392: 397-416.
97. Liu L, Shen RY, Kapatos G, Chiodo LA. Dopamine neuron membrane physiology: characterization of the transient outward current (IA) and demonstration of a common signal transduction pathway for IA and IK. Synapse 1994; 17: 230-40.
98. Greif GJ, Lin YJ, Liu JC, Freedman JE. Dopamine-modulated potassium channels on rat striatal neurons: specific activation and cellular expression. J Neurosci 1995; 15: 4533-44.
99. 2 dopamine, but not A1 adenosine, receptor-mediated inhibition of striatal dopamine release. J Neurochem 1991; 57: 147-52.
100. 2 dopamine receptors associated with inhibition of dopamine release from rat neostriatum are independent of cyclic AMP. Neurosci Lett 1986; 71: 192-6.
101. 3 dopamine autoreceptors do not activate G-protein-gated inwardly rectifying potassium channel currents in substantia nigra dopamine neurons. J Neurosci 2003; 23: 5693-7.
102. 2+ currents in rat anterior pituitary cells. Neuron 1992; 8: 455-63.
103. 4 dopamine receptors. Br J Pharmacol 1994; 112: 728-34.
104. 2 (short) dopamine receptors expressed in differentiated NG108-15 cells. Br J Pharmacol 1994; 111: 1061-6.
105. 3 dopamine receptor inhibits P/Q-type calcium channels and secretory activity in AtT-20 cells. J Neurosci 1999; 19: 1698-707.
106. Okada Y, Miyamoto T, Toda K. Dopamine modulates a voltagegated calcium channel in rat olfactory receptor neurons. Brain Res 2003; 968: 248-55.
107. Surmeier DJ, Eberwine J, Wilson CJ, Cao Y, Stefani A, Kitai ST. Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc Natl Acad Sci USA 1992; 89: 10178-82.
108. Surmeier DJ, Kitai ST. D1 and D2 dopamine receptor modulation of sodium and potassium currents in rat neostriatal neurons. Prog Brain Res 1993; 99: 309-24.
109. Voyno-Yasenetskaya T, Conklin BR, Gilbert RL, Hooley R, Bourne HR, Barber DL. G alpha 13 stimulates Na-H exchange. J Biol Chem 1994; 269: 4721-4.
110. 2 subfamily of dopamine receptors. Cell Signal 1996; 8: 453-9.
111. 2L glioma cells. J Neurochem 1998; 71: 980-90.
112. 2 dopamine receptors. J Neurochem 1998; 70: 2139-46.
113. 2 receptors. Biochem Biophys Res Commun 1999; 256: 33-40.
114. 2S receptor activation in BALB/c 3T3 cells. Mol Cell Biol 2000; 20: 1497-506.
115. 2L Receptor Stimulation of the Mitogen-Activated Protein Kinase Pathway Is Dependent on trans-Activation of the Platelet-Derived Growth Factor Receptor. Mol Pharmacol 2001; 60: 92-103.
116. 2 receptor. Mol Endocrinol 2004; 18: 640-52.
117. 2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells. Mol Pharmacol 1991; 39: 364-9.
118. 2 receptor synergism. Nature 1991; 353: 164-7.
119. 4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells. J Biol Chem 1994; 269: 11813-9.
120. 2 receptors potentiate arachidonate release via activation of cytosolic, arachidonate-specific phospholipase A2. J Neurochem 1995; 64: 2765-72.
121. 3 receptor. Life Sci 1999; 64: 939-51.
122. Piomelli D, Greengard P. Lipoxygenase metabolites of arachidonic acid in neuronal transmembrane signalling. Trends Pharmacol Sci 1990; 11: 367-73.
123. 2 receptor-dependent potentiation of arachidonic acid release. J Neurochem 1992; 59: 379-82.
124. L'hirondel M, Cheramy A, Godeheu G, Glowinski J. Effects of arachidonic acid on dopamine synthesis, spontaneous release, and uptake in striatal synaptosomes from the rat. J Neurochem 1995; 64: 1406-9.
125. Zhang L, Reith ME. Regulation of the functional activity of the human dopamine transporter by the arachidonic acid pathway. Eur J Pharmacol 1996; 315: 345-54.
126. Mitchell R, McCulloch D, Lutz E, Johnson M, MacKenzie C, Fennell M, et al. Rhodopsin-family receptors associate with small G proteins to activate phospholipase D. Nature 1998; 392: 411-4.
127. Senogles SE. The D2s dopamine receptor stimulates phospholipase D activity: A novel signaling pathway for dopamine. Mol Pharmacol 2000; 58: 455-62.
128. Kurose H, Katada T, Amano T, Ui M. Specific uncoupling by islet-activating protein, pertussis toxin, of negative signal transduction via alpha-adrenergic, cholinergic, and opiate receptors in neuroblastoma x glioma hybrid cells. J Biol Chem 1983; 258: 4870-5.
129. Bokoch GM, Katada T, Northup JK, Hewlett EL, Gilman AG. Identification of the predominant substrate for ADP-ribosylation by islet activating protein. J Biol Chem 1983; 258: 2072-5.
130. 3 dopamine receptors in vivo. J Neurosci 2007; 27: 881-5.
131. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 2008; 132: 125-36.
132. Frebel K, Wiese S. Signalling molecules essential for neuronal survival and differentiation. Biochem Soc Trans 2006; 34: 1287-90.
133. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004; 101: 5099-104.
134. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005; 122: 261-73.
135. Alimohamad H, Rajakumar N, Seah YH, Rushlow W. Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 2005; 57: 533-42.
136. Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol 2007; 10: 7-19.
137. Beaulieu JM, Caron MG. Beta-arrestin goes nuclear. Cell 2005; 123: 755-7.
138. Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, et al. A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell 2005; 123: 833-47.
139. Mailman RB, Huang X. Dopamine receptor pharmacology. In Koller W, Melamed E, Eds. Handbook of clinical neurology (3rd series) Parkinson's disease and related disorders. Amsterdam Elsevier 2007; pp. 77-105.
140. Mailman RB. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 2007; 28: 390-6.
141. Hjorth S, Clark D, Svensson K, Carlsson A, Thorberg O. Subchronic administration of (-)-3-PPP and central dopamine receptor sensitivity changes. J Neural Transm 1985; 64: 187-98.
142. 2 receptor, on tyrosine hydroxylation in rat striatal slices. Life Sci 1988; 42: 343-9.
143. 2 receptor antagonist. Life Sci 1988; 42: 1941-54.
144. Zhang X, Nakata Y, Kikuchi T, Segawa T. Interactions of 7-[3-(4-[2,3-dimethylphenyl]piperazinyl)- propoxy]-2(1H)-quinolinone binding in rat striatum: effects of lesions. Pharm Res 1990; 7: 280-2.
145. Hinzen D, Hornykiewicz O, Kobinger W, Pichler L, Pifl C, Schingnitz G. The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment. Eur J Pharmacol 1986; 131: 75-86.
146. 2 agonist, in the treatment of negative symptoms of chronic schizophrenia. Biol Psychiatry 1993; 33: 687-93.
147. 2 receptor agonists in the treatment of schizophrenia. Psychopharmacol Bull 1989; 25: 393-7.
148. Duval F, Mokrani MC, Macher JP, Crocq MA, Castro JO, Bailey P, et al. Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients. Psychopharmacology 1993; 110: 177-80.
149. 4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 447-53.
150. 3H]hydroxy-N,N-di-n-propyl-2- aminotetralin. Proc Natl Acad Sci USA 1992; 89: 8155-9.
151. 2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. J Pharmacol Exp Ther 2004; 309: 921-35.
152. Coward DM, Dixon AK, Urwyler S, Vigouret JM. Pharmacological properties of SDZ 208-912: a potential high potency, non-classical neuroleptic. Pharmacopsychiatry 1988; 21: 312-3.
153. Coward DM, Dixon AK, Urwyler S, White TG, Enz A, Karobath M, et al. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. J Pharmacol Exp Ther 1990; 252: 279-85.
154. Wright JL, Caprathe BW, Downing DM, Glase SA, Heffner TG, Jaen JC, et al. The discovery and structure-activity relationships of 1,2,3,6-tetrahydro-4-phenyl-1-[(arylcyclohexenyl)alkyl]pyridines. Dopamine autoreceptor agonists and potential antipsychotic agents. J Med Chem 1994; 37: 3523-33.
155. 3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse 2006; 60: 599-608.
156. Wolf WA. SLV-308. Solvay. Curr Opin Investig Drugs 2003; 4: 878-82.
157. Heusler P, Newman-Tancredi A, Castro-Fernandez A, Cussac D. Differential agonist and inverse agonist profile of antipsychotics at D(2L) receptors coupled to GIRK potassium channels. Neuropharmacology 2007; 52: 1106-13.
158. Heusler P, Newman-Tancredi A, Loock T, Cussac D. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells. Eur J Pharmacol 2008; 581: 37-46.
159. Claustre Y, Peretti DD, Brun P, Gueudet C, Allouard N, Alonso R, et al. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacology 2003; 28: 2064-76.
160. 3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. Journal of Neural Transmission - General Section 1994; 98: 39-55.
161. Tedroff J, Torstenson R, Hartvig P, Sonesson C, Waters N, Carlsson A, et al. Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity. Synapse 1998; 28: 280-7.
162. Nilsson M, Carlsson A, Markinhuhta KR, Sonesson C, Pettersson F, Gullme M, et al. The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 677-85.
163. Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM, et al. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1- propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl- piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 2006; 318: 810-8.
164. Tadori Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol 2007; 574: 103-11.
165. Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl) 2008; 200: 317-31.
166. Anonymous. Bifeprunox - Atypical Antipsychotic Drug. Drugdevelopment- technology.com 2009.
167. 2 receptor partial agonist. Eur J Pharmacol 2006; 552: 36-45.
168. Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D. A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists. Curr Pharm Des 2008; 14(15): 1525-52.
169. Fowler CJ. "The tools of the trade" - an overview of the pharmacology of the endocannabinoid system. Curr Pharm Des 2008; 14(23): 2254-65.
170. Muller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 2008; 14(14): 1452-65.